Merck’s Terns Pharma Buy: A High-Stakes Play on a Rare-Cancer Catalyst Before Keytruda’s Patent Cliff

Merck is moving fast to secure its future, nearing a roughly $6 billion all-cash deal to acquire biotech firm Terns Pharma. The potential acquisition, which could be finalised in the coming days, values Terns at a premium to its market capitalisation of about $5.3 billion. This is a high-stakes, opportunistic bet to bolster Merck's pipeline ahead of a looming cliff.

The strategic context is urgent. The blockbuster cancer drug Keytruda generated sales of more than $30 billion in 2025 and accounted for nearly half of Merck's total revenue last year. It could face generic competition as early as 2028. To offset this massive future revenue loss, Merck has accelerated its dealmaking, having already snapped up Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion last year. The Terns deal fits squarely into this aggressive portfolio-building push.

The Clinical Payoff: TERN-701's Phase 1 Signal

The premium Merck is paying hinges on one asset: TERN-701, an investigational drug for chronic myeloid leukaemia (CML), a rare cancer. The early clinical data is the deal's primary justification. At the December ASH meeting, Terns reported that in a heavily pretreated, refractory patient group, 64% achieved a major molecular response by 24 weeks. That figure, described as "unprecedented" by the company, represents a strong efficacy signal in a tough-to-treat population.

This is the near-term catalyst. The Phase 1 data suggests TERN-701 could be a best-in-class therapy, particularly for patients who have failed prior treatments. Its mechanism as an allosteric BCR::ABL1 inhibitor positions it to compete directly with Novartis's Scemblix, a key drug in the CML market. The early safety profile also looks encouraging, with no dose-limiting toxicities observed.

Yet the clinical payoff remains unproven. This is Phase 1 data from a small, select cohort. The real test will be larger, later-stage trials that confirm these results in broader populations and demonstrate a clear clinical advantage. For now, the deal values a promising signal, not a proven product. The premium paid assumes this early promise will translate into a marketable drug, a bet that will be validated or challenged over the coming years.

The Immediate Market Setup and Next Catalysts

The immediate setup is defined by a binary event: the deal's finalization. Merck is nearing a roughly $6 billion all-cash deal to acquire Terns, with a close possible in the coming days. The primary catalyst is the closing itself, which will shift the premium paid from a speculative headline to a settled accounting entry. Following that, the market will watch for regulatory and shareholder approvals, which are standard hurdles but could introduce minor delays.

The key watchpoint, however, is the upcoming clinical data for TERN-701. The Phase 1 data presented at ASH in December was the deal's foundation, showing 64% achieved a major molecular response by 24 weeks in a tough patient group. That readout validated the premium paid for Terns' pipeline. The next major catalyst will be the release of more expansive data from the CARDINAL trial, which was scheduled for the December ASH meeting. Investors should monitor for any updates on that trial's progression, as it will be the first real-world test of whether the early promise can be sustained.

For now, the tactical focus is on the deal's closure. Once completed, the market will begin to price in the integration of TERN-701 into Merck's portfolio. A more immediate data point to watch will be Merck's Q1 2026 earnings report. While not directly tied to the Terns deal, it will provide a critical update on Keytruda's sales trajectory as the company braces for its potential exclusivity loss. It will also offer any commentary on the integration progress of its recent acquisitions, including Verona and Cidara, setting the stage for how aggressively Merck plans to deploy capital in its pipeline-building push.